W. Burke

发表

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours

J. Larkin, M. Gore, P. Lorigan, 2011, British Journal of Cancer.

An Investigation into the Utility of a Multi-compartmental, Dynamic, System of the Upper Gastrointestinal Tract to Support Formulation Development and Establish Bioequivalence of Poorly Soluble Drugs

M. Yasin, P. Dickinson, Ric Barker, 2012, The AAPS Journal.

First-in-human phase I trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors.

M. Ranson, U. Banerji, E. Harrington, 2012 .

Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer.

J. Bendell, H. Burris, H. Hochster, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract A168: First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor.

E. Raymond, R. Kurzrock, A. Naing, 2011 .

First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor.

E. Raymond, R. Kurzrock, A. Naing, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours

Bing-he Xu, Jianming Xu, J. Shentu, 2019, Cancer Chemotherapy and Pharmacology.

Clinical evaluation of the potential drug–drug interactions of savolitinib: Interaction with rifampicin, itraconazole, famotidine or midazolam

G. Scarfe, W. Burke, K. Vishwanathan, 2021, British journal of clinical pharmacology.

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014

M. Ranson, U. Banerji, E. Harrington, 2015, Clinical Cancer Research.

A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.

S. Sundar, A. Robinson, T. Powles, 2016, European urology.

Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1/2 mutations.

Y. Drew, R. Plummer, M. Ranson, 2012 .

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma

E. Raymond, R. Kurzrock, G. Schwartz, 2012, British Journal of Cancer.

Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours

S. Aamdal, D. Pietersma, D. Tan, 2012, British Journal of Cancer.

An Investigation into the Utility of a Multi-compartmental, Dynamic, System of the Upper Gastrointestinal Tract to Support Formulation Development and Establish Bioequivalence of Poorly Soluble Drugs

M. Yasin, P. Dickinson, Ric Barker, 2012, The AAPS Journal.